Compare BridgeBio Pharma Inc (BBIO) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Honeywell International Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Honeywell International Inc trades at $230.15 (market cap $76.99B). The key difference: Honeywell International Inc is far larger — about 4.6× BridgeBio Pharma Inc's market cap, and Honeywell International Inc pays a 1.15% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HON | |
|---|---|---|
Market Cap | $16.61B | $76.99B |
Sector | Health | Industrials |
52-Week High | $90.17 | $248.79 |
52-Week Low | $47.29 | $188.14 |
Enterprise Value | $18.16B | $101.79B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Honeywell Technologies (HON) trades at $246.19, up 2.26% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company has completed strategic divestitures to focus on automation. Key financials show a P/E of 9.47, net income margin of 21.58%, and robust cash flow from operations of $6.41B in 2025. The stock is near its consensus price target of $320.54, indicating potential upside.
Outlook is positive due to earnings momentum and portfolio simplification, but risks include integration challenges from spinoffs and macroeconomic sensitivity. Institutional sentiment is bullish with 66.7% buy ratings. Investors should monitor execution of growth strategies in building automation and aerospace segments for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
